LAMA4 and sarcoma: An earlier independent study identified two MHC I-restricted neoepitopes within the neoantigens Lama4 and Alg8 that were spontaneously immunogenic upon implantation of the d42m1-T3 sarcoma, and SLP vaccines spanning these MHC I-restricted neoepitopes generated a pronounced neoepitope-specific IFNγ+CD8+ CTL response that effectively treated tumors16.